GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rapid Dose Therapeutics Corp (XCNQ:DOSE) » Definitions » EBITDA

Rapid Dose Therapeutics (XCNQ:DOSE) EBITDA : C$-3.95 Mil (TTM As of Aug. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Rapid Dose Therapeutics EBITDA?

Rapid Dose Therapeutics's EBITDA for the three months ended in Aug. 2024 was C$-0.81 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Aug. 2024 was C$-3.95 Mil.

During the past 3 years, the average EBITDA Growth Rate was -45.30% per year. During the past 5 years, the average EBITDA Growth Rate was 18.80% per year. During the past 10 years, the average EBITDA Growth Rate was -75.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of Rapid Dose Therapeutics was 28.70% per year. The lowest was -520.70% per year. And the median was -16.10% per year.

Rapid Dose Therapeutics's EBITDA per Share for the three months ended in Aug. 2024 was C$-0.01. Its EBITDA per share for the trailing twelve months (TTM) ended in Aug. 2024 was C$-0.04.

During the past 3 years, the average EBITDA per Share Growth Rate was -30.70% per year. During the past 5 years, the average EBITDA per Share Growth Rate was 27.10% per year. During the past 10 years, the average EBITDA per Share Growth Rate was 13.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of Rapid Dose Therapeutics was 58.50% per year. The lowest was -193.20% per year. And the median was 16.00% per year.


Rapid Dose Therapeutics EBITDA Historical Data

The historical data trend for Rapid Dose Therapeutics's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rapid Dose Therapeutics EBITDA Chart

Rapid Dose Therapeutics Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24
EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.37 -0.99 -7.59 -2.92 -3.03

Rapid Dose Therapeutics Quarterly Data
Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.42 -0.73 -1.54 -0.87 -0.81

Competitive Comparison of Rapid Dose Therapeutics's EBITDA

For the Biotechnology subindustry, Rapid Dose Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rapid Dose Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rapid Dose Therapeutics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Rapid Dose Therapeutics's EV-to-EBITDA falls into.


Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Rapid Dose Therapeutics's EBITDA for the fiscal year that ended in Feb. 2024 is calculated as

Rapid Dose Therapeutics's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Feb. 2024, Rapid Dose Therapeutics's EBITDA was C$-3.03 Mil.

Rapid Dose Therapeutics's EBITDA for the quarter that ended in Aug. 2024 is calculated as

Rapid Dose Therapeutics's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Aug. 2024, Rapid Dose Therapeutics's EBITDA was C$-0.81 Mil.

EBITDA for the trailing twelve months (TTM) ended in Aug. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-3.95 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Rapid Dose Therapeutics  (XCNQ:DOSE) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


Rapid Dose Therapeutics EBITDA Related Terms

Thank you for viewing the detailed overview of Rapid Dose Therapeutics's EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Rapid Dose Therapeutics Business Description

Traded in Other Exchanges
Address
1121 Walkers Line, Unit 3, Burlington, ON, CAN, L7N 2G4
Rapid Dose Therapeutics Corp is a Canadian biotechnology company revolutionizing drug delivery through innovation. The company's flagship product QuickStrip is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients (nutraceuticals, pharmaceuticals, vaccines, and cannabis) that are delivered quickly into the bloodstream resulting in rapid onset of the active ingredient.
Executives
Mark Upsdell Director
Brian Howlett Director

Rapid Dose Therapeutics Headlines

No Headlines